The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection was declared by the World Health Organization as pandemic in the early 2020. The clinical spectrum of coronavirus disease 2019 (COVID-19) include asymptomatic and symptomatic cases, including dry cough, fatigue, fever, shortness of breath, and gastrointestinal symptoms. However, increased immune inflammatory responses to stimuli can result in the overproduction of pro-inflammatory cytokines, immunopathological complications and death in patients infected with COVID-19. Given the anti-inflammatory effects of Naproxen, this study evaluated the effect of naproxen on IL-1β, TNF-a, IL-6, IFN-γ and TGF-β in COVID-19 patients. According to the results, the serum levels of IFN-γ and TGF-β cytokines significantly decreased in the patients after the treatment with naproxen. In addition, the naproxen treatment was found effective in reducing the serum level of IL-6 and IL-1β in patients with COVID-19, though it did not significantly change the serum level of TNF-a. Overall, the findings demonstrated the effectiveness of naproxen on pro-inflammatory cytokines by regulating their serum levels in COVID-19 patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.